Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen

Assay and Drug Development Technologies

Volumn 8, Issue 1, 2010, Pages 47-62

  Tanaka, Kenji ^a,d   Koresawa, Mitsunori ^a,e   Iida, Masato ^a,d   Fukasawa, Kazuhiro ^a   Stec, Erica ^b   Cassaday, Jason ^b   Chase, Peter ^b,e   Rickert, Keith ^b,e   Hodder, Peter ^b,f   Takagi, Toshimitsu ^c   Komatani, Hideya ^a,g  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ROSETTA INPHARMATICS   (United States)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

^e ASTELLAS PHARMA INC   (Japan)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE LIBRARY; POLO LIKE KINASE 2; PROTEIN SERINE THREONINE KINASE;

ANTIBODY DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FLUOROMETRY; HIGH THROUGHPUT SCREENING; HUMAN; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL;

AMINO ACID SEQUENCE; CELL CYCLE PROTEINS; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 77649170169     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0212     Document Type: Article

References (43)

1. Hunter T: Signaling-2000 and beyond. Cell 2000;100:113-127.
2. Cohen P: Protein kinases-the major drug targets of the twenty-first century?. Nat Rev Drug Discov 2002;1:309-315.
3. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 2002;298:1912-1934.
4. Scapin G: Protein kinase inhibition: Different approaches to selective inhibitor design. Curr Drug Targets 2006;7:1443-1454.
5. Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y: Pharmacological and functional comparison of the polo-like kinase family: Insight into inhibitor and substrate specificity. Biochemistry 2007;46:9551-9563.
6. von Ahsen O, Bomer U: High-throughput screening for kinase inhibitors. Chembiochem 2005;6:481-490.
7. Wesche H, Xiao SH, Young SW: High throughput screening for protein kinase inhibitors. Comb Chem High Throughput Screen 2005;8:181-195.
8. Kolb AJ, Kaplita PV, Hayes DJ, Park Y-W, Pernell C, Major JS, et al.: Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Disc Today 1998;3:333-342.
9. Klumpp M, Boettcher A, Becker D, Meder G, Blank J, Leder L, et al.: Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format. J Biomol Screen 2006;11:617.
10. Kemp BE, Pearson RB: Design and use of peptide substrates for protein kinases. Methods Enzymol 1991;200:121-134.
11. Panse S, Dong L, Burian A, Carus R, Schutkowski M, Reimer U, et al.: Profiling of generic anti-phosphopeptide antibodies and kinases with peptide microarrays using radioactive and fluorescence-based assays. Mol Divers 2004;8:291-299.
12. Barr FA, Silljé HHW, Nigg EA: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5:429-440.
13. Xie S, Xie B, Lee MY, Dai W: Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 2005;24:277-286.
14. van Vugt MA, Medema RH: Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005;24:2844-2859.
15. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287-291.
16. Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-328.
17. McInnes C, Mezna M, Fischer PM: Progress in the discovery of polo-like kinase inhibitors. Curr Topics Med Chem 2005;5:181-197.
18. Zhang W, Fletcher L, Muschel RJ: The role of polo-like kinase1 in the inhibition of centrosome separation after ionizing radiation. J Biol Chem 2005;280:42994-42999.
19. Santamaria A, Neef R, Eberspächer U, Eis K, Husemann M, Mumberg D, et al.: Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate the functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 2007;18:4024-4036.
20. Karlsson-Rosenthal C, Millar JBA: Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006;16:285-292.
21. Toyoshima-Morimoto F, Taniguchi E, Nishida E: Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002;3:341-348.
22. Nakajima H, Toyoshima-Morimoto F, Taniguchi E, Nishida E: Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem 2003;278:25277-25280.
23. Sadler TM, Achilleos M, Ragunathan S, Pitkin A, LaRocque J, Morin J, et al.: Development and comparison of two nonradioactive kinase assays for I kappa B kinase. Anal Biochem 2004;326:106-113.
24. Chung CC, Ohwaki K, Schneeweis JE, Stec E, Varnerin, JP, Goudreau PN, et al.: A fluorescence-based thiol quantification assay for ultra-high-throughput screening for inhibitors of coenzyme A production. Assay Drug Dev Technol 2008;6:361-374.
25. Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, et al.: A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 2002;1:9-19.
26. Hodder P, Mull R, Cassaday J, Berry K, Strulovici B: Miniaturization of intracellular calcium functional assays to 1536-well plate format using a fluorometric imaging plate reader. J Biomol Screen 2004;9:417-426.
27. Zhang JH, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
28. Hodder P, Cassaday J, Peltier R, Berry K, Inglese J, Feuston B, et al.: Identification of metabotropic glutamate receptor antagonists using an automated highthroughput screening system. Anal Biochem 2003;313:246-254.
29. Toyoshima-Morimoto E, Taniguchi E, Shinya N, Iwamatsu A, Nishida E: Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001;410:215-220.
30. Yuan J, Eckerdt F, Bereiter-Hahn J, Kurunci-Csacsko E, Kaufmann M, Strebhardt K: Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 2002;21:8282-8292.
31. Jang YJ, Lin CY, Ma S, Erikson RL: Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acd Sci USA 2002;99:1984-1989.
32. Arai T, Haze K, Iimura-Morita Y, Machida T, Iida M, Tanaka K, et al.: Identification of beta-catenin as a novel substrate of polo-like kinase 1. Cell Cycle 2008;7:3556-3563.
33. Jang YJ, Ma S, Terada Y, Erikson RL: Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase 1. J Biol Chem 2002;277:44115-44120.
34. Kemp BE, Pearson RB: Protein kinase recognition sequence motif. Trends Biochem Sci 1990;15:342-346.
35. Nesbit CE, Tersak JM, Prochownik EV: MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004-3016.
36. Fehrmann F, Laimins LA: Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 2003;22:5201-5207.
37. Horesh D, Sapir T, Francis F, Wolf SG, Caspi M, Elbaum M, et al.: Doublecortin, a stabilizer of microtubules. Hum Mol Genet 1999;8:1599-1610.
38. Sharlow ER, Leimgruber S, Shun TY, Lazo JS: Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1. Assay Drug Dev Technol 2007;5:723-735.
39. Pawson T, Nash P: Assembly of cell regulatory systems through protein interaction domains. Science 2003;300:445-452.
40. Comley J: Assay interference: a limiting factor in HTS? Drug Disc World 2003; Summer:91-98.
41. Zhang JH, Wu X, Sills MA: Probing the primary screening by multiple replicate testing: A quantitative analysis of hit confirmation and false screening results of a biochemical assay. J Biomol Screen 2005;10:695-704.
42. Wu X, Sills MA, Zhang JH: Further comparison of primary hit identification by different assay technologies and effects of assay measurement viability. J Biomol Screen 2005;10:581-589.
43. von Ahsen O, Schmidt A, Klotz M, Parczyk K: Assay concordance between SPA and TR-FRET in high-throughput-screening. J Biomol Screen 2006;11:606-616.